Compare Trump Media and Technology Group Corp (DJT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Sanofi SA — how do they compare? Trump Media and Technology Group Corp trades at $8.14 (market cap $2.28B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 41.7× Trump Media and Technology Group Corp's market cap, and Sanofi SA pays a 6.01% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Sanofi SA for 94 Days on average.
| DJT | SNY | |
|---|---|---|
Market Cap | $2.28B | $95.18B |
Volume | 3,148,379 | 2,995,646 |
Sector | Media | Health |
52-Week High | $17.07 | $52.34 |
52-Week Low | $7.06 | $39.51 |
Typical Hold Time | 17 Days | 94 Days |
Enterprise Value | $2.35B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.11, down 1.34% with bearish technical signals. The company reported $3.68M revenue in 2025 but a net loss of $712M, with negative margins and cash flow challenges. Recent news highlights a proposed merger with TAE Technologies and ongoing volatility linked to political developments and strategic shifts.
Outlook remains high-risk due to persistent losses and speculative sentiment. The merger with TAE offers potential diversification into fusion energy, but profitability concerns and insider selling weigh on investor confidence. Key risks include execution hurdles and dependence on political narratives.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
